Pharma & Biotech

ImmunityBio has become a battleground stock where two opposing forces are digging in. Retail traders have piled into the biotech...

The gulf between operational progress and market perception is rarely wider than at Onco-Innovations these days. The oncology biotech has...

The stock has surged more than 16% over the past month, yet the enthusiasm on Wall Street remains conspicuously muted....

Shares of Outlook Therapeutics have exploded higher since late March, surging roughly 950% after the FDA accepted the company’s regulatory...

The euphoria surrounding Bayer’s landmark victory before the US Supreme Court has propelled its shares to €48.40, a near-38% surge...

Outlook Therapeutics has escaped the threat of expulsion from the Nasdaq Capital Market, but the relief is tempered by a...

BioNTech is simultaneously tightening its belt and opening its wallet, a dual move that signals both caution and ambition as...

Canopy Growth shareholders have had little to cheer about this year, but the past few days delivered two distinct catalysts...

Ocugen enters a make-or-break stretch that will test both its science and its stock. The gene therapy developer, which has...

The U.S. Supreme Court handed Bayer a landmark win on June 25, effectively closing the most potent legal avenue for...